Cyproheptadine Hydrochloride 1.5mg + Tricholine Citrate 55mg in Flavoured Sorbitol Base is a liquid oral formulation containing two active ingredients incorporated into a flavored sorbitol-based vehicle. The formulation requires controlled handling of the active ingredients, accurate dosing, uniform dispersion, appropriate viscosity, and consistent filling. For pharmaceutical companies developing a diversified liquid formulation portfolio, this product can be incorporated into a professionally managed PCD Pharma Franchise range.
The presence of a sorbitol-based liquid vehicle provides a defined formulation environment for the active ingredients and supporting excipients. Flavoring components may be incorporated to provide the desired organoleptic profile according to the finalized product specification. Manufacturing controls focus on ingredient compatibility, homogeneity, pH, viscosity, microbial quality, fill volume, and stability.
The manufacturing process begins with the qualification of Cyproheptadine Hydrochloride and Tricholine Citrate. Each active pharmaceutical ingredient is evaluated against predefined raw-material specifications before being released for production. Applicable tests may include identity, assay, purity, moisture content, and other relevant quality attributes.
Accurate dispensing is particularly important because the two active ingredients are incorporated at different quantities. Cyproheptadine Hydrochloride is present at 1.5mg, while Tricholine Citrate is present at 55mg in the specified formulation. Calibrated weighing equipment and documented dispensing procedures help maintain the intended composition.
The sorbitol base and other formulation components are also qualified before use. Depending on the finalized formulation, these may include purified water, flavoring agents, viscosity modifiers, preservatives, sweetening components, and other suitable excipients.
Compatibility assessment may be conducted during formulation development to evaluate interactions between the APIs, sorbitol vehicle, flavoring system, and other excipients. The final formulation is maintained according to the approved product specification.
Preparation of the flavored sorbitol base is an important stage in manufacturing. Sorbitol and other liquid components are processed according to a defined manufacturing sequence using suitable pharmaceutical-grade equipment.
The active ingredients are incorporated into the prepared vehicle through controlled addition and mixing. Mixing speed, processing time, temperature, and ingredient-addition sequence may be controlled to achieve a homogeneous formulation.
Because Cyproheptadine Hydrochloride is present at a comparatively low concentration, suitable premixing or controlled dilution techniques may be considered during formulation development to promote uniform distribution throughout the bulk liquid.
Tricholine Citrate is incorporated according to the approved formulation quantity and processing sequence. Continuous or intermittent agitation may be maintained where necessary to prevent settling or concentration gradients.
Parameters such as appearance, color, odor, pH, viscosity, and specific gravity may be monitored during in-process evaluation. Where appropriate, the bulk formulation may undergo filtration before proceeding to the filling stage.
Flavoring is incorporated according to the finalized formulation specification and selected to maintain a consistent organoleptic profile. The flavoring system must remain compatible with the active ingredients, sorbitol base, and other excipients.
Once the bulk formulation meets the required in-process parameters, it is transferred to the liquid-filling stage. Suitable filling equipment is used to dispense predetermined quantities into approved pharmaceutical containers.
Fill-volume accuracy is monitored throughout production to maintain consistency between individual units. Filling equipment is calibrated and inspected before use, while line-clearance procedures help prevent product mix-ups.
The selected bottle and closure system should be compatible with the liquid formulation. Containers are inspected before filling, and closure integrity is checked after filling and capping.
Labels and secondary packaging are applied according to controlled packaging procedures. Product name, composition, batch number, manufacturing information, expiry details, storage requirements, and other applicable labeling information are verified during the packaging process.
Quality control for Cyproheptadine Hydrochloride 1.5mg + Tricholine Citrate 55mg in Flavoured Sorbitol Base involves evaluation of raw materials, bulk formulation, and finished packaged product.
Finished-product testing may include identification, assay of the active ingredients, appearance, color, odor, pH, viscosity, specific gravity, fill volume, microbial quality, and other parameters included in the approved specification.
Because the formulation contains a lower-strength Cyproheptadine component alongside a higher-quantity Tricholine Citrate component, suitable analytical procedures and representative sampling are important for demonstrating uniformity.
Analytical methods used for quantitative testing should be appropriately validated or verified for their intended application. Laboratory instruments are calibrated and maintained according to established quality procedures.
Stability studies are conducted under defined storage conditions and testing intervals to evaluate the formulation throughout its proposed shelf life. Parameters may include appearance, pH, viscosity, specific gravity, assay, related substances, microbial quality, and container-closure integrity where applicable.
Stability monitoring helps identify potential changes in the liquid formulation and supports establishment of appropriate product specifications.
Packaging protection is important for maintaining the quality of this flavored sorbitol-based liquid formulation during storage, transportation, and distribution. Suitable pharmaceutical-grade bottles, closures, measuring devices, and secondary packaging may be selected according to the finalized formulation requirements.
The packaging system should maintain compatibility with the sorbitol-based formulation and provide suitable protection during handling. Proper sealing helps minimize leakage and unwanted environmental exposure.
For companies operating in the PCD Pharma Franchise segment, Cyproheptadine Hydrochloride 1.5mg + Tricholine Citrate 55mg in Flavoured Sorbitol Base can be integrated into a broader liquid pharmaceutical portfolio through systematic API qualification, controlled sorbitol-base preparation, accurate ingredient dispensing, flavor incorporation, liquid processing, quality testing, stability monitoring, and professional packaging.
A structured product-development framework covering raw-material sourcing, formulation compatibility, controlled mixing, in-process testing, filling, packaging, and stability evaluation helps maintain consistency across production batches.
Standardized manufacturing records, defined quality specifications, calibrated equipment, appropriate analytical controls, and organized inventory planning further support systematic product management. This approach allows the formulation to be maintained as a consistent component of a broader pharmaceutical portfolio and PCD Pharma Franchise distribution network.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech